The collaboration comes as Novo faces competitive pressure from Eli Lilly's Zepbound, which has overtaken its Wegovy weight-loss drug in the U.S. prescription market since mid-March. "Novo Nordisk has a rich history of innovation in obesity and diabetes, and we are capitalizing on our leadership in this field to develop a robust pipeline," explained Marcus Schindler, Novo's Chief Scientific Officer.